CVC Highlight: Opioids: The good, the bad, and the future - Veterinary Medicine
Medicine Center
DVM Veterinary Medicine Featuring Information from:


CVC Highlight: Opioids: The good, the bad, and the future
Misconceptions and misuse make some veterinarians hesitant to turn to this form of pain control in pets. Here's why opioids remain an excellent option in many cases.



1. Lascelles BDX, Capner CA, Waterman-Pearson AE. Current British veterinary attitudes to perioperative analgesia for cats and small mammals. Vet Rec 1999;145:601-604.

2. De Leo JA, Tawfik VL, LaCroix-Fralish ML. The tetrapartite synapse: path to CNS sensitization and chronic pain. Pain 2006;122(1-2):17-21.

3. Watkins LR, Milligan ED, Maier SF. Spinal cord glia: new players in pain. Pain 2001;93(3):201-205.

4. Taylor PM, Robertson SA, Dixon MJ, et al. Morphine, pethidine and buprenorphine disposition in the cat. J Vet Pharmacol Ther 2001;24(6):391-398.

5. Niedfeldt RL, Robertson SA. Postanesthetic hyperthermia in cats: a retrospective comparison between hydromorphone and buprenorphine. Vet Anaesth Analg 2006;33(6):381-389.

6. Erichsen HK, Hao JX, Xu XJ, et al. Comparative actions of the opioid analgesics morphine, methadone and codeine in rat models of peripheral and central neuropathic pain. Pain 2005;116(3):347-358.

7. Monteiro ER, Figueroa CD, Choma JC, et al. Effects of methadone, alone or in combination with acepromazine or xylazyine, on sedation and physiologic values in dogs. Vet Anaesth Analg 2008;35(6):519-527.

8. Steagall PV, Carnicelli P, Taylor PM, et al. Effects of subcutaneous methadone, morphine, buprenorphine or saline on thermal and pressure thresholds in cats. J Vet Pharmacol Ther 2006;29(6):531-537.

9. Krotscheck U, Boothe DM, Little AA. Pharmacokinetics of buprenorphine following intravenous administration in dogs. Am J Vet Res 2008;69(6):722-727.

10. Robertson SA, Taylor PM, Sear JW. Systemic uptake of buprenorphine by cats after oral mucosal administration. Vet Rec 2003;152(22):675-678.

11. Abbo LA, Ko JC, Maxwell LK, et al. Pharmacokinetics of buprenorphine following intravenous and oral transmucosal administration in dogs. Vet Ther 2008;9(2):83-93.

12. Sawyer DC, Rech RH, Durham RA, et al. Dose response to butorphanol administered subcutaneously to increase visceral nociceptive threshold in dogs. Am J Vet Res 1991;52(11):1826-1830.

13. Grimm KA, Tranquilli WJ, Thurmon JC, et al. Duration of nonresponse to noxious stimulation after intramuscular administration of butorphanol, medetomidine, or a butorphanol-medetomidine combination during isoflurane administration in dogs. Am J Vet Res 2000;61(1):42-47.

14. Hay JL, La Vincente SF, Somogyi AA, et al. Potentiation of buprenorphine antinociception with ultra-low dose naltrexone in healthy subjects. Eur J Pain 2011;15(3):293-298.

15. Tzschentke TM, Christoph T, Kogel B, et al. (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther 2007;323(1):265-276.

16. Buprenorphine SR. Fort Collins, Colo: ZooPharm. Available at

17. Smith LJ, KuKanich B, Hogan BK, et al. Pharmacokinetics of a controlled-release liposome-encapsulated hydromorphone administered to healthy dogs. J Vet Pharmacol Ther 2008;31(5):415-422.

18. Krugner-Higby L, Smith L, Schmidt B, et al. Experimental pharmacodynamics and analgesic efficacy of liposome-encapsulated hydromorphone in dogs. J Am Anim Hosp Assoc 2011;47(3):185-195.

19. Carr, DB. Opioid side effects. In: IASP Pain Clinical Updates, April 2007 XV:2.

20. Gervitz C. Update on the management of opioid-induced constipation. Topics Pain Management 2007;23(3):1-5.

21. DeLeo JA, Sorkin LS, Watkins LR. Immune and glial regulation of pain. Seattle Wash: IASP Press, 2007.

22. Tremblay J, Hamet P. Genetics of pain, opioids, and opioid responsiveness. Metabolism 2010;59(Suppl 1):S5-S8.


Click here